Loading organizations...
Frequency Therapeutics is a Lexington, Massachusetts-based biotechnology company that develops regenerative medicine treatments aimed at restoring hearing by regenerating inner ear sensory cells and promoting remyelination for multiple sclerosis. The clinical-stage enterprise initially secured $2.5 million in early seed capital in 2015 before raising a $28 million Series B funding round in 2017. In October 2020, the organization transitioned to the public equities market through an initial public offering that generated approximately $70 million in gross proceeds by pricing five million shares at $14 each. Backed by lead investor RA Capital Management, the firm leverages foundational research originating from institutions like MIT and Harvard Medical School, and subsequently completed a reverse merger in May 2024. Frequency Therapeutics was originally founded in 2014 by former MassBio chairman David Lucchino, alongside academic researchers Robert Langer and Jeffrey Karp.
Frequency Therapeutics has raised $136.0M across 3 funding rounds.
Frequency Therapeutics has raised $136.0M in total across 3 funding rounds.
Frequency Therapeutics has raised $136.0M in total across 3 funding rounds.
Frequency Therapeutics's investors include Joseph Edelman, Axil Capital, Cobro Ventures, Deerfield Management, Mizuho Securities Principal Investment, Polaris Founders Capital, RTW Investments, Joel Marcus, Marc Cohen, DF Investments, Emigrant Capital, Korea Investment Partners.
Frequency Therapeutics has raised $136.0M across 3 funding rounds. Most recently, it raised $62.0M Series C in July 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 23, 2019 | $62M Series C | Joseph Edelman | Axil Capital, Cobro Ventures, Deerfield Management, Mizuho Securities Principal Investment, Polaris Founders Capital, RTW Investments | Announced |
| Jan 1, 2019 | $42M Series B | Axil Capital | Joel Marcus, Marc Cohen, DF Investments, Emigrant Capital, Korea Investment Partners, Polaris Founders Capital, Daguan Wang | Announced |
| Apr 11, 2017 | $32M Series A | Marc Cohen | Alexandria Venture Investments, Emigrant Capital, Korea Investment Partners, Morningside Ventures | Announced |
Frequency Therapeutics is a clinical-stage biopharmaceutical company that develops regenerative medicines aimed at restoring lost sensory function, primarily focusing on hearing loss. Its flagship product, FX-322, uses progenitor cell activation (PCA) technology to stimulate the body's own cells to regenerate damaged inner ear tissue, addressing sensorineural hearing loss, a condition with limited treatment options. The company serves patients with hearing impairment and is expanding its regenerative approach into other therapeutic areas, supported by ongoing clinical trials and strategic partnerships[1][3].
Founded in 2014 and headquartered in Lexington, Massachusetts, Frequency Therapeutics was established to harness the body's natural regenerative potential through innovative cell activation technology. The idea emerged from scientific advances in progenitor cell biology, aiming to create therapies that stimulate tissue repair rather than relying on external cell transplants. Early clinical trials of FX-322 demonstrated promising results, marking pivotal moments that validated the company's approach and attracted investor interest[1][2].
Frequency Therapeutics rides the growing trend of regenerative medicine and precision biologics, which aim to repair or replace damaged tissues at the cellular level. The timing is favorable due to advances in cell biology, increased investment in biotech innovation, and a rising prevalence of sensory disorders in aging populations. Market forces such as unmet clinical needs in hearing loss and degenerative diseases create strong demand for novel therapies. Frequency’s work influences the broader ecosystem by advancing progenitor cell activation as a viable therapeutic strategy, potentially opening new avenues in regenerative medicine[1][3].
Frequency Therapeutics is positioned to potentially transform treatment for hearing loss and other degenerative conditions through its PCA platform. The next critical milestones include successful late-stage clinical trial results and regulatory approvals for FX-322. Trends shaping its journey include advances in regenerative biology, growing healthcare focus on sensory impairments, and increasing biotech funding. If successful, Frequency could expand its influence by validating progenitor cell activation as a new therapeutic paradigm, attracting further research and investment in this space[1][3].
In summary, Frequency Therapeutics combines cutting-edge science with a clear clinical focus on sensory restoration, aiming to address significant unmet medical needs through innovative regenerative therapies.
